Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ALK F1174V||neuroblastoma||sensitive||ALK Inhibitor||Brigatinib||Preclinical - Cell culture||Actionable||In a preclinical study, neuroblastoma cells harboring ALK F1174V were sensitive to Alunbrig (brigatinib) in culture and in vivo, resulting in inhibition of both Alk activity and cell proliferation (PMID: 27049722).||27049722|
|ALK F1174V||neuroblastoma||predicted - sensitive||ALK Inhibitor||Crizotinib||Case Reports/Case Series||Actionable||In a Phase I/II trial (ADVL0912), Xalkori (crizotinib) treatment resulted in an objective response of 15% (3/20) in pediatric patients with relapsed/refractory neuroblastoma harboring ALK activating mutations or amplifications, a patient harboring ALK F1174V stayed on treatment for 3 cycles until disease progression (PMID: 33568345; NCT00939770).||33568345|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|